The insulin-like growth factor-1 and expression of its binding protein‑3 in chronic hepatitis C and hepatocellular carcinoma

Adamek,Agnieszka; Kasprzak,Aldona; Mikoś,Hanna; Przybyszewska,Wiesława; Seraszek-Jaros,Agnieszka; Czajka,Arkadiusz; Sterzyńska,Karolina; Mozer-Lisewska,Iwona

doi:10.3892/or.2013.2546

The insulin-like growth factor-1 and expression of its binding protein‑3 in chronic hepatitis C and hepatocellular carcinoma

Authors:
- Agnieszka Adamek
- Aldona Kasprzak
- Hanna Mikoś
- Wiesława Przybyszewska
- Agnieszka Seraszek-Jaros
- Arkadiusz Czajka
- Karolina Sterzyńska
- Iwona Mozer-Lisewska
View Affiliations

Affiliations: Department of Infectious Diseases, Poznan University of Medical Sciences, Poznan, Poland, Department of Histology and Embryology, Poznan University of Medical Sciences, Poznan, Poland, Department of Pediatric Endocrinology and Diabetes, Poznan University of Medical Sciences, Poznan, Poland, Department of Clinical Pathomorphology, Poznan University of Medical Sciences, Poznan, Poland
Published online on: June 19, 2013 https://doi.org/10.3892/or.2013.2546
Pages: 1337-1345

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of growth factors produced by the liver, including insulin-like growth factor-1 (IGF-1) and its main binding protein, IGF binding protein-3 (IGFBP-3), in hepatitis C virus (HCV)-associated carcinogenesis has only partially been recognized and there is not much data available on the local expression of IGF-1 and IGFBP-3 in chronic hepatitis C (CH‑C). Therefore, the aim of the present study was to evaluate the IGF‑1 and IGFBP‑3 serum levels and tissue expression in liver biopsies of CH‑C patients (n=37) and hepatocellular carcinoma (HCC) samples (n=61) as related to age- and gender-matched control serum samples (n=15) and healthy liver samples (n=10). Serum concentrations of IGF-1 (S-IGF-1) and IGFBP‑3 (S-IGFBP‑3) were measured by the ELISA method. Tissue expression of proteins was detected using ABC immunocytochemistry and evaluated applying a spatial visualization technique. Concentrations of S-IGF-1 and hepatic expression of IGF-1 (H-IGF-1) proved to be lower in CH-C compared to the controls. No significant differences were detected in the concentration of S-IGFBP-3 between the studied groups but the S-IGF-1/IGFBP-3 ratio in the CH-C group was significantly lower compared to the control. H-IGFBP-3 was higher in CH-C compared to those in the control and HCC. In HCC, lower expression of H-IGF-1 was detected compared to the control and a higher H-IGF-1/IGFBP-3 ratio compared to CH-C. A negative correlation was detected between S-IGF-1 and S-IGF-1/IGFBP-3 ratio, on the one hand, and age, grading and concentration of α-fetoprotein (AFP) on the other, while H-IGFBP-3 was negatively correlated with BMI in the CH‑C group. In patients with CH‑C, the H‑IGF‑1/IGFBP‑3 ratio was higher compared to that of the S‑IGF‑1/IGFBP‑3 ratio. The studies documented a disturbed H‑IGF‑1 and H‑IGFBP‑3 in CH‑C, which may be of significance in carcinogenesis. Examination of serum concentration and tissue expression of the two proteins and, first of all, estimation of the IGF‑1/IGFBP‑3 ratio may provide additional (to the estimation of IGF‑1 and AFP) non-invasive markers in HCV‑related liver injury.

View Figures

View References

1	Fattovich G, Stroffolini T, Zagni I and Donato F: Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127:S35–S50. 2004. View Article : Google Scholar : PubMed/NCBI
2	Rehermann B and Nascimbeni M: Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 5:215–229. 2005. View Article : Google Scholar : PubMed/NCBI
3	Colombo M: Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 19:263–269. 1999. View Article : Google Scholar : PubMed/NCBI
4	Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 11:383–393. 2004. View Article : Google Scholar : PubMed/NCBI
5	Kasprzak A and Adamek A: Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepatol Res. 38:1–26. 2008. View Article : Google Scholar : PubMed/NCBI
6	Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G and Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocellular cells against drug-induced apoptosis. Biochem Pharmacol. 86:1003–1015. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kasprzak A and Adamek A: The insulin-like growth factor (IGF) signaling axis and hepatitis C virus-associated carcinogenesis (Review). Int J Oncol. 41:1919–1931. 2012.PubMed/NCBI
8	Daughday WH and Rotweien P: Insulin-like growth factors I and II: peptide, messenger ribonucleic acid, and gene structures, serum and tissue concentrations. Endocr Rev. 10:68–91. 1989. View Article : Google Scholar : PubMed/NCBI
9	Zarilli R, Bruni CB and Riccio A: Multiple levels of control of insulin-like growth factor gene expression. Mol Cell Endocrinol. 101:R1–R14. 1994. View Article : Google Scholar : PubMed/NCBI
10	Juul A, Bang P, Hertel NT, et al: Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 78:744–752. 1994.PubMed/NCBI
11	Brabant G and Wallaschofski H: Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary. 10:129–133. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kostecka Y and Blahovec J: Insulin-like growth factor binding proteins and their functions (minireview). Endocr Regul. 33:90–94. 1999.PubMed/NCBI
13	Le Roith D, Bondy C, Yakar S, Liu JL and Butler A: The somatomedin hypothesis: 2001. Endocr Rev. 22:53–74. 2001.
14	Elmlinger MW, Kühnel W, Weber MM and Ranke MB: Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med. 42:654–664. 2004. View Article : Google Scholar : PubMed/NCBI
15	Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van Doorn J and Juul A: Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal. 13:166–172. 1999. View Article : Google Scholar : PubMed/NCBI
16	Juul A, Dalgaard P, Blum WF, et al: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 80:2534–2542. 1995.PubMed/NCBI
17	Mattsson A, Svensson D, Schuett B, Osterziel KJ and Ranke MB: Multidimensional reference region for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum healthy adults. Growth Horm IGF Res. 18:506–516. 2008. View Article : Google Scholar : PubMed/NCBI
18	Raslan HM, Elhosary Y, Ezzat WM, Rasheed EA and Rasheed MA: The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. Trans R Soc Trop Med Hyg. 104:429–432. 2010. View Article : Google Scholar : PubMed/NCBI
19	Blum WF, Albertsson-Wikland K, Rosberg S and Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab. 76:1610–1616. 1993.PubMed/NCBI
20	Wu JC, Daughaday WH, Lee SD, et al: Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia. J Lab Clin Med. 112:589–594. 1988.PubMed/NCBI
21	Kratzsch J, Blum WF, Schenker E and Keller E: Regulation of growth hormone (GH), insulin-like growth factor (IGF) I, IGF binding proteins -1, -2, -3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes. 103:285–291. 1995. View Article : Google Scholar : PubMed/NCBI
22	Völzke H, Nauck M, Rettig R, Dörr M, Higham C, Brabant G and Wallaschofski H: Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol. 161:705–713. 2009.PubMed/NCBI
23	Rehem RN and El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as a parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology. 58:949–954. 2011.PubMed/NCBI
24	Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N and Vyzantiadis A: Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology. 50:814–816. 2003.PubMed/NCBI
25	Lorenzo-Zúñiga V, Bartolí R, Masnou H, Montoliu S, Morillas RM and Planas R: Serum concentration of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci. 52:3245–3250. 2007.PubMed/NCBI
26	Nikolić JA, Todorović V, Bozić M, et al: Serum insulin-like growth factor (IGF)-II is more closely associated with liver disfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta. 294:169–177. 2000.PubMed/NCBI
27	Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C and Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer. 87:118–121. 2000. View Article : Google Scholar : PubMed/NCBI
28	Wu YL, Ye J, Zhang S, Zhong J and Xi RP: Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol. 10:2740–2743. 2004.PubMed/NCBI
29	Mazziotti G, Sorvillo F, Morisco F, et al: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 95:2539–2545. 2002. View Article : Google Scholar
30	Okan A, Cömlekçi A, Akpinar H, Okan I, Yeşil S, Tankurt E and Simşek I: Serum concentration of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol. 35:1212–1215. 2000. View Article : Google Scholar : PubMed/NCBI
31	Raslan H, Ezzat W, Ahmed M and Rasheed E: Insulin growth-factor-1 and insulin-like growth factor binding protein-3 in Egyptian patients with chronic hepatitis C. Arch Med Sci. 3:46–51. 2007.
32	Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML and Wang SN: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI
33	Morali G, Shitrit AB, Eran M, Freier S, Reinus C and Braverman D: Hepatic production of insulin-like growth factors in normal and diseased liver. Hepatogastroenterology. 52:1511–1515. 2005.PubMed/NCBI
34	Stefano JT, Correa-Giannella ML, Ribeiro CMF, Alves VAF, Massarollo PCB, Machado MCC and Giannella-Neto D: Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol. 28:3821–3828. 2006.PubMed/NCBI
35	Huynh H, Chow PKH, Ooi LLP and Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ. 13:115–122. 2002.
36	Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 8:45–62. 1997. View Article : Google Scholar : PubMed/NCBI
37	Kasprzak A, Adamek A, Przybyszewska W, et al: Expression of IGF-1 and viral proteins (C, NS3, NS5A) in the livers of patients with chronic HCV infection. Adv Clin Exp Med. 20:263–273. 2011.
38	Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 24:289–293. 1996. View Article : Google Scholar : PubMed/NCBI
39	Kasprzak A, Adamek A, Biczysko W, et al: Intracellular expression of the proliferative marker Ki-67 and viral proteins (NS3, NS5A and C) in chronic, long lasting hepatitis C virus (HCV) infection. Folia Histochem Cytobiol. 45:357–366. 2007.PubMed/NCBI
40	Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 29:577–580. 1981. View Article : Google Scholar : PubMed/NCBI
41	Kaczmarek E and Strzelczyk R: From two to three-dimensional visualisation of structures in light and confocal microscopy - applications for biomedical studies. Current Issues on Multidisciplinary Microscopy Research and Education. Mendez-Vilas A and Labajos-Broncano L: (FORMATEX microscopy book series no II). Formatex Research Centre; Badajoz: pp. 289–295. 2005
42	Mahdy KA, Ahmed HH, Mannaa F and Abdel-Shaheed A: Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J Gastroenterol. 13:785–790. 2007. View Article : Google Scholar : PubMed/NCBI
43	Aimaretti G, Boschetti M, Corneli G, et al: Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. J Endocrinol Invest. 31:445–449. 2008. View Article : Google Scholar : PubMed/NCBI
44	Andreassen M, Nielsen K, Raymond I, Kristensen LØ and Faber J: Characteristics and reference ranges of insulin-like growth factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians. Scand J Clin Lab Invest. 69:880–885. 2009. View Article : Google Scholar : PubMed/NCBI
45	Rosario PW: Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol. 54:477–481. 2010. View Article : Google Scholar : PubMed/NCBI
46	Holmes MD, Pollak MN and Hankinson SE: Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev. 11:862–867. 2002.
47	Colakošlu O, Taşkiran B, Colakoğlu G, Kizildağ S, Ari Ozkan F and Unsal B: Serum insulin like growth factor-1 (IGF-1) and insulin growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol. 18:245–249. 2007.
48	Plöckinger U, Krüger D, Bergk A, Weich V, Wiedenmann B and Berg T: Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. Am J Gastroenterol. 102:2724–2731. 2007.PubMed/NCBI
49	Ichikawa T, Nakao K, Hamasaki K, et al: Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development on non-alcoholic fatty liver disease. Hepatol Int. 1:287–294. 2007. View Article : Google Scholar : PubMed/NCBI
50	Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ and Hill DJ: Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab. 79:1871–1876. 1994.PubMed/NCBI
51	Ross RJM, Chew SL, D’Souza Li L, et al: Expression of IGF-I and IGF-binding protein genes in cirrhotic liver. J Endocrinol. 149:209–216. 1996. View Article : Google Scholar : PubMed/NCBI
52	Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A and D’Agostino L: Increased IGF-I:IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf). 59:699–706. 2003. View Article : Google Scholar : PubMed/NCBI